Skip to main content
Premium Trial:

Request an Annual Quote

Leena Das-Young

Guardant Health has appointed Leena Das-Young to serve as general manager of its LUNAR program. In her new role, Das-Young will oversee all work applying Guardant Health's technology and database of more than 70,000 clinical Guardant360 assay results, toward new applications in early-stage cancer, such as residual detection, recurrence monitoring, and early detection.

Prior to joining Guardant, Das-Young was vice president and head of the late phase strategy development group at Pfizer's oncology group, where she was responsible for a portfolio of oncology programs including Ibrance, Xalkori, Besponsa, Sutent, lorlatinib, and others. Prior to her roles in product development, she served in various commercial roles responsible for several successful launches at both Pfizer and Bayer.  She holds BS and Doctor of Pharmacy degrees from Purdue University.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.